Serena Monti , Giuseppe Palma , Ting Xu , Radhe Mohan , Zhongxing Liao , Laura Cella
{"title":"Prediction of Grade 4 radiation-induced lymphopenia during chemoradiation therapy for lung cancer patients: Insights from two past trials","authors":"Serena Monti , Giuseppe Palma , Ting Xu , Radhe Mohan , Zhongxing Liao , Laura Cella","doi":"10.1016/j.phro.2025.100782","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Purpose</h3><div>Radiation-induced lymphopenia (RIL) is a significant side effect associated with radiation therapy (RT) with important prognostic implications. We developed and tested a normal tissue complication probability (NTCP) model for Grade 4 (G4) RIL in patients with locally advanced Non-Small-Cell Lung Cancer (NSCLC) who underwent concurrent chemotherapy and RT, analyzing data from patients enrolled in two clinical trials.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively analyzed the data from NCT00915005 (MDA-cohort) and NCT00533949 (RTOG0617-cohort) trials. After finding the candidate predictors of G4-RIL, defined as absolute lymphocyte count (ALC) at nadir < 0.2*10<sup>9</sup> cells/l during RT, we trained an NTCP model on the MDA-cohort and tested it on the RTOG-cohort, based on common available variables in the two cohorts. Model performance was assessed in terms of discrimination and calibration.</div></div><div><h3>Results</h3><div>In the MDA-cohort, 55 out of 161 (34%) patients developed G4-RIL, while in the RTOG-cohort 16 out of 227 (7%) developed this condition. The relative volume of healthy lungs receiving at least 5 Gy (V<sub>5Gy</sub>) and baseline ALC were selected as predictors in an NTCP model, with good discriminative performances (cross validated ROC-AUC: 0.68). The predictive value of V<sub>5Gy</sub> was confirmed in the RTOG0917-cohort (ROC-AUC: 0.67), although its validation was limited with suboptimal calibration, potentially due to discrepancies between cohorts.</div></div><div><h3>Conclusions</h3><div>Baseline ALC and lung V<sub>5Gy</sub> were identified as predictors for G4-RIL, consistent with findings from previous studies. Treatment plan optimization aiming at reducing low-dose bath in the lungs could be an effective strategy for severe RIL mitigation.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"34 ","pages":"Article 100782"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physics and Imaging in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405631625000879","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Purpose
Radiation-induced lymphopenia (RIL) is a significant side effect associated with radiation therapy (RT) with important prognostic implications. We developed and tested a normal tissue complication probability (NTCP) model for Grade 4 (G4) RIL in patients with locally advanced Non-Small-Cell Lung Cancer (NSCLC) who underwent concurrent chemotherapy and RT, analyzing data from patients enrolled in two clinical trials.
Materials and Methods
We retrospectively analyzed the data from NCT00915005 (MDA-cohort) and NCT00533949 (RTOG0617-cohort) trials. After finding the candidate predictors of G4-RIL, defined as absolute lymphocyte count (ALC) at nadir < 0.2*109 cells/l during RT, we trained an NTCP model on the MDA-cohort and tested it on the RTOG-cohort, based on common available variables in the two cohorts. Model performance was assessed in terms of discrimination and calibration.
Results
In the MDA-cohort, 55 out of 161 (34%) patients developed G4-RIL, while in the RTOG-cohort 16 out of 227 (7%) developed this condition. The relative volume of healthy lungs receiving at least 5 Gy (V5Gy) and baseline ALC were selected as predictors in an NTCP model, with good discriminative performances (cross validated ROC-AUC: 0.68). The predictive value of V5Gy was confirmed in the RTOG0917-cohort (ROC-AUC: 0.67), although its validation was limited with suboptimal calibration, potentially due to discrepancies between cohorts.
Conclusions
Baseline ALC and lung V5Gy were identified as predictors for G4-RIL, consistent with findings from previous studies. Treatment plan optimization aiming at reducing low-dose bath in the lungs could be an effective strategy for severe RIL mitigation.